Shares of ABOS inventory opened at $3.08 on Thursday. The business has a fifty working day relocating typical of $4.54 and a 200 day going ordinary of $6.66. Acumen Prescription drugs has a 1 yr very low of $3.04 and a 1 year higher of $26.98.
Hedge cash and other institutional traders have a short while ago additional to or decreased their stakes in the small business. BlackRock Inc. grew its situation in shares of Acumen Prescribed drugs by 8.4% all through the 4th quarter. BlackRock Inc. now owns 3,109,670 shares of the company’s inventory valued at $21,021,000 just after getting an supplemental 240,879 shares for the duration of the time period. Goldman Sachs Group Inc. grew its place in shares of Acumen Prescribed drugs by 408.% for the duration of the 4th quarter. Goldman Sachs Group Inc. now owns 323,264 shares of the company’s stock valued at $2,185,000 soon after obtaining an supplemental 259,629 shares during the period. Geode Funds Management LLC grew its placement in shares of Acumen Pharmaceuticals by 59.4% for the duration of the 4th quarter. Geode Cash Management LLC now owns 171,879 shares of the company’s inventory valued at $1,161,000 right after obtaining an supplemental 64,073 shares all through the period of time. State Avenue Corp grew its situation in shares of Acumen Pharmaceuticals by 11.6% through the 4th quarter. Condition Street Corp now owns 111,363 shares of the company’s inventory valued at $753,000 just after attaining an supplemental 11,588 shares through the time period. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Acumen Prescription drugs throughout the 4th quarter valued at about $585,000. Institutional traders and hedge resources have 64.42% of the company’s stock.
A amount of equities analysts not long ago issued reports on ABOS shares. Credit history Suisse Team decreased their target cost on Acumen Prescribed drugs from $26.00 to $17.00 and established an “outperform” ranking for the firm in a investigate be aware on Tuesday, March 29th. Financial institution of The usa upgraded Acumen Prescribed drugs from a “neutral” rating to a “buy” ranking and diminished their cost objective for the business from $16.00 to $14.00 in a investigation note on Friday, January 21st. Ultimately, Zacks Financial investment Analysis decreased Acumen Prescription drugs from a “hold” rating to a “sell” ranking in a study notice on Tuesday. 1 exploration analyst has rated the inventory with a offer rating and four have supplied a purchase ranking to the firm. Based on knowledge from MarketBeat, the corporation has a consensus score of “Buy” and an normal value concentrate on of $18.35.
About Acumen Prescribed drugs (Get Ranking)
Acumen Prescription drugs, Inc, a clinical-phase biopharmaceutical organization, discovers and develops therapies for the procedure of Alzheimer’s condition. The firm focuses on advancing a qualified immunotherapy drug applicant ACU193, a humanized monoclonal antibody that is in Section I clinical-phase to focus on soluble amyloid-beta oligomers.
Receive Information & Ratings for Acumen Prescription drugs Daily – Enter your e mail tackle underneath to receive a concise each day summary of the latest news and analysts’ ratings for Acumen Prescription drugs and connected corporations with MarketBeat.com’s Free daily e-mail publication.